Suven Life Sciences Limited has issued the notice for its 37th Annual General Meeting (AGM), scheduled to be held on Tuesday, August 25, 2026, at 11:30 a.m. IST through Video Conferencing (VC) / Other Audio Visual Means (OAVM). The meeting will address critical corporate governance matters, including a material related party transaction involving the appointment of Dr. Madhavi Jasti, the re-appointment of an Independent Director beyond the age of seventy-five, and a significant reallocation of unutilised proceeds from a recent preferential issue. These developments signal the company's strategic focus on strengthening its overseas clinical development capabilities while optimising capital deployment amidst a widening standalone loss of ₹5,486.28 lakhs in FY26.

Related Party Transaction: Appointment of Dr. Madhavi Jasti

The Board seeks shareholder approval for the appointment of Dr. Madhavi Jasti, daughter of Chairman & Managing Director Mr. Venkateswarlu Jasti and Whole-time Director Mrs. Sudha Rani Jasti, to oversee Medical Affairs in the company’s wholly owned subsidiaries in the USA and Singapore. This engagement qualifies as a Material Related Party Transaction under Regulation 23(4) of SEBI LODR because her proposed annual remuneration exceeds 10% of the company’s consolidated turnover.

Dr. Jasti, who holds 1,000 equity shares in the listed entity, will be responsible for clinical trials, medical monitoring, and regulatory compliance. Her initial remuneration is set at USD 400,000 per annum, with a maximum ceiling of USD 1,000,000 per annum, payable by the overseas subsidiaries. The Board justified the appointment based on her MD degree from the USA and over ten years of experience in clinical development, stating that the arrangement is at arm’s length and in the ordinary course of business. Promoter directors and their relatives are barred from voting on this resolution.

Variation in Utilisation of Preferential Issue Proceeds

Shareholders will also vote on a special resolution to vary the utilisation of proceeds from the preferential issue of 6,40,02,999 convertible warrants raised at ₹134 per warrant, aggregating ₹857.64 crores. As of March 31, 2026, only ₹26,068.64 lakhs had been utilised, leaving an unutilised balance of ₹59,695.38 lakhs. The company proposes to reallocate funds primarily due to lower-than-expected capital expenditure for its new R&D centre in Genome Valley, Hyderabad, and increased funding requirements for clinical development programs.

The revised allocation shifts ₹7,500.00 lakhs from the CAPEX object (reduced from ₹20,000.00 lakhs to ₹12,500.00 lakhs) to clinical development expenses (increased from ₹40,000.00 lakhs to ₹47,500.00 lakhs). This reallocation aims to support the expansion of clinical trial activities across multiple jurisdictions without altering the fundamental purpose of the fund raise. CRISIL Ratings Limited continues to monitor the utilisation of these proceeds.

Board Re-appointments and Governance

The AGM agenda includes the re-appointment of Prof. Seyed E. Hasnain as a Director retiring by rotation. Additionally, shareholders must approve the re-appointment of Dr. Vajja Sambasiva Rao as an Independent Director for a second consecutive term of five years, commencing January 21, 2027. This requires a Special Resolution because Dr. Rao will attain the age of seventy-five years on January 21, 2027, necessitating justification under Regulation 17(1A) of SEBI Listing Regulations. The Board cited his extensive experience in project management and corporate governance as key reasons for retaining him beyond the standard age limit.

Financial Context and E-Voting Details

The corporate actions come against a backdrop of significant financial losses. Suven Life Sciences reported a standalone loss of ₹5,486.28 lakhs in FY26, up from ₹4,707.98 lakhs in FY25, driven by high R&D expenditures. The consolidated loss widened to ₹27,634.41 lakhs, largely attributable to clinical development costs incurred by its US subsidiary. No dividend was recommended for FY26.

Remote e-voting for the AGM will commence on Friday, August 21, 2026, at 9:00 a.m. IST and conclude on Monday, August 24, 2026, at 5:00 p.m. IST. The cut-off date for determining voting rights is Tuesday, August 18, 2026. Members holding shares as on this date are eligible to cast their votes electronically through the KFin Technologies Limited platform.

Suven Life Sciences is charting an ambitious course in neuroscience research and global expansion, with plans to achieve a major breakthrough in central nervous system (CNS) research by 2026-27 and the launch of a new branch in Singapore, according to a report by Mint.

Strategic Focus on Central Nervous System Research

The company has outlined plans for significant advancements in neuroscience, targeting a breakthrough in CNS research within the 2026-27 timeframe. CNS disorders represent a complex and high-value therapeutic area, and Suven Life Sciences' focus in this domain underscores its commitment to specialized pharmaceutical research and development.

Singapore Branch Expansion

Alongside its research ambitions, Suven Life Sciences is expanding its international footprint with the establishment of a Singapore branch. The move reflects the company's intent to strengthen its global presence and potentially access new markets and partnerships in the Asia-Pacific region.

Key Highlights

• Suven Life Sciences is targeting major advancements in neuroscience research.
• The company aims for a CNS research breakthrough by 2026-27.
• A new Singapore branch is being established as part of its global expansion strategy.

These strategic initiatives position Suven Life Sciences as an active participant in the high-stakes CNS therapeutic segment, while its Singapore expansion broadens the company's international operational base.